36 I - 2012

....





,

 (' )

 -
,

016907

SSN

w w w . e e l i a . o r g

K.

H -
1790-8124

215, 115 25

Editorial

, .

,
.

.
, ,

....,
,
, - 570.000.000 - , , - 45 . , ,
,
, .
, .
, - , .... , - . ,
-
, .... -
, . - ,
, - .

, ,
, .
. , ,
, - ,
.
, - , , ,
( , - .
),

....
(,
...
) -

,

.
,
.

,
.

,
.. , , .
,
,

, .
, , .
,
.

, 6

.


,
.

,
.

.
,
,


.
, .
,

.
,
.
,

.

, ,
.
:
- ,
- ,
- ,
-

1% ,
-
,
- .
,

....

.
,

,
.

.
.

, ,


.

;

.

,


. -

.

, , .
,

.

:
-
,
, .
- .
- , ,
.
-
.

, ,


,

.
, ,
.

....

EEYEPOEAEMAT IATP
- E 36 - 2012
IoI: O (....)
215, 115 25 , . - fax: 210 6753918 .: 6945 333334, 6944 542664 e-mail: info@eelia.org website: www.eelia.org
EKOTH - : , , E.E.I.A.
IOIKHTIKO ....
..............................................
........................................................................
............................................

..................

...................................................

.......................

..........................................................................................................................................................................................................
............................................................................................................................................................................................................... , .
....................................................................................................................................................................................................... ,
................................................................................................................................................................... ,
............................................................................................................................ ,
.......................................................................................................................................................................................
. ...................................................................................................................................................................... , /
..........................................................................................................................................................................................
........................................................................................................................................................................... , E
-...................................................................................................................................... ,
................................................................................................................................................................................., ./
. ....................................................................................................................................................................................
............................................................................................................................................................, /
......................................................................................................................................................................................, .
..........................................................., . , / /, / Laser
.........................................................................................................................................., . / '
...................................................................................................................................................................... ,
.................................................................................................................................................................
................................................................................................................................................................................................................ ,
............................................................................................................................. , / - ,
............................................................................................................................................ ,
. ............................................................................................................................................................................................ ,
......................................................................................................................................., / Metropolitan
............................................................................................................................................................................
.............................................................................................................................................................................. -,
.............................................................................................................................................................................................,
..................................................................................................................................................................................
...................................................................................................................................................... ,
.....................................................................................................................................................................
................................................................................................ ,
................................................................................................................................................................................... , .
........................................................................................................................................................................................,
TOYH HMHTPIO................................................................................................................................... K K I
......................................................................................................................................................................................................................
XATHIANNH TEANO.................................................................................................................................................................... , K
...................................................................................................................................................................................................... ,
......................................................................................................................................................................................................................... ,
......................................................................................................................................................................................................................................YNTH ,
..................................................................................................................................................................................................................................... ,
..................................................................................................................................................................................................................................... ,

EI.......................................................................................................................................................................................................................... ....
........................................................................................................................................................................................................................................ ....
........................................................................................................................................................................................................................................ ....
.................................................................................................................................................................................................................. ....
..........................................................................................................................................................................................................................
.............................................................................................................................................................................................................

.....................................................................................................................................................................................................................................
.....................................................................................................................................................................................................................................................
. .......................................................................................................................................................................................................................................

I .................................................................................................................................................................................. 4, 152 34 ,

10

215, 151 25
.: 210 6777590, Fax: 210 6756352
kafkas@otenet.gr www.kafkas-publications.com

H Eo o o
o o o , ,
o o .
o o o
o oo o 210 6777590
o : kafkas@otenet.gr o fax: 210 6756352.

36 - 2012

...

.

Ditorial

, 4/09/2012

OY

OY .



12 E

21 

26
31
(' )
36

37 

....
: ) CD
Word jpg (300
dpi) (glossy), ) kafkas@otenet.gr
.....
: ) (
: , , , ,
fax, e-mail), ) (),
) , ) ( ), ) . : ,
, , CD
. : : ....
, 215, , 115 25 : . ,
.: 210 6777590, fax: 210 6756352 e-mail: kafkas@otenet.gr

12

. .
. .
,
.

, .
, . , , .
40% 13%.
. ,
.
,
,

.
.

...
,

.
, 4/09/2012

,

.
, ,
,
.

,
,

,

( , , , ) . 3918/2011.

-

,
,
,
,
.
,
, ,
. ,
.
,

,

,

.

,

.
, , , . . ,

, .


.


.
.



.

...
.....
, .....

, 3/09/2012

. ,
. ,
- :
1) ....,
2)
,
3) -

570.000.000 ,
4) 45 ,
5)
, ,
6)
( , ),
7) 13


(, )
,
8)
.
- ,
.
, , .
,

.
.

,

.

.

.... .
.

, 31/08/2012
., /
. ,
, ,
, , ,
,

,
, .
.
.

, 30/08/2012
. , .
,
, ,
, , .

,

. 14

,
.
. ,
,
, . ,
( ) ,
, ,

. :
1) -



.
2) ,
( , ).
3)
, ,
, .
,
.
, ,
, , .


.

,

. , , ,
, , ,
, , (.
, Factoring).
, .
.

- ... ,

, 29/08/2012
- :
)
)
)
)

)
.

)
, .

, .
.

(- ),
.....

, 27/08/2012
, ,
.

,
.
,
15


.

.

, , 4 5

.
,
,
, .

, .
,
,
, .
, -

.

,
( ,
). ,
" ". .
, .

,
,
, .

, , .
,
, , ..... .
.

,

,24/08/2012
, .
,
,
,
, .

, , .
,
,
.

16

,
, . ,
1) , 2) , 3) .
,

, ,
.
.

...
.
,

, 23/08/2012
.
, ,
.
,
,
2009 29.343 .
,
,
apriori
,
.
, , ,
, . -

, , . , , ,
.


, .
,
,

, .
.

22.8.2012
.


, 22/08/2012
. ,

,
36402/22-8-2012
, ,
31875/21-8-2012 ,

18

, , .
1) ,
, ,
,


,
, .
,
,

. ,
,
.
2) ,
,

,
,

.
,
. 24 , ,
,
, 21 .3918/2011.

3) , ,

. ,
,
, , ,
.
, , . , .
,
6/8/2012,


,
.
.

.


, 20/08/2012


,
. ....
....,
.


,

, 570.000.000
, ,
...., 2010 2011
20

23/8/2012 1/9/2012,


.....

. ....
....
.
.

.
, /,

, /, - ...,
.
, . /

()
-

.

.
,
o .
, , .
-
(. 1).
, , ,

, . ,

,


, ,
, , .
, 1.
.
.

. .
3 4 (). .
().

1. -

,
, -
. , , .

.
, . ,
,
, - . 80%
60-65
.
, , , , , ..(. 1)
()
, , .
. ,
, , . ,
, .
.

-, ,

21



,

.
,, : ,


2 .
, 1

2 .

,
:
)
(bulging disc),
) (protrusion)
2.
,
4-5 . ) (extrusion)

, ,

)(sequestration,
-,
2 ,
). .
,
(), ,
(, ),
. ,

, () .
, () .
,

, .
22

2.
()

(, ) .
.

CT MRI
, ,
.
, ,
.
,


. (.
4,5).
3.
.
CT MRI.

MRI
4-5, 5-6,

6-7 ,
, ,
5-6,


.
.
T1W T2W. ,
T2W.

,
.
Luschka (. 4,5) 3 7
.
, ,

, .


(Facet) .
, , , ()
. ,
.

4. ) , ) Luschka,
)

Luschka.


.
( ) ,
,
.

3.
() : , -
.
. ()
45 50 .
. .

, . .
, 1.
( )
, . Lushcka , .
, .
, .

,
.
90% . 90%
.
,
.

, ,

.
:
) 57% , 40 .
)  (bulging
disc) 20% , 45-54 57%
64 .
) 
8% ,
50 .
)  20%
, 40 .



.
,

,
, .
.
:
.
2 . ( 1
2 ).
23



: ) (bulging disc), )
(protrusion), ) (extrusion), ) (sequestration). ,

, .
.
, .
. , ,
. , . , :
) ,
2 ,
) ,

) , .
().


2
.

4. 


,
.
55 . , 4%
.
,
12 . 30%.
(MRI)
1




( )

B12

24

3:

.

.
.
. ()
. (, , .)
,
(.. ) 1. (High signal changes)
.

5(-): () , 2 .

. ()
:
,
. ()
: .
,
.


,
().
.

0,8.

.
.

,
(spinolaminar line).
17mm (15-20mm).
(
) 13mm , .
(CT MRI).
,
Pavlov, -

1. renstein D., Wiessel S., and Boden S. The neck pain. Philadelphia. Saunders,
1997.
2. Oostendrop RAB. Funktionele Vestebrobasillaire insufficintie.Nijmegen.
Catholic University, 1988. Dissertation.
3. B . . , ,
1995.
4.  . . , ,
1997.
5. W
 risley D M, Sparto P J, Whitney S L et all. Cervicogenic dizziness : a rewiew
of diagnosis and treatment. J Orthop Phys Ther 2000;30: 755-66.
6. Dvorak J and Dvorak V. Manual Medicine -- Diagnosis, 2nd ed. Thieme
Medical Publishers, New York, 1990.
7. D
 os Winkel. Diagnosis and treatment of the Spine. Gaithersburg. An Aspen
Publ. 1996.
8. Sjaastad O, Bovim G. Cervicogenic headache. The differentiation from common
migraine. An overview. Funct Neurol 1991; 6:93-100.
9.
 . , 2 ,
, 2001.
10.  . . : .
- , , , 2002.
11.  . ,
. : . -. ,
, 2002.
12. B
 ovim G, Schrader H, Sand T. Neck pain in the general population. Spine.
Jun 15 1994;19(12):1307-9.
13. Parke WW, Sherk HH. Normal adult anatomy. In: Sherk HH, Dunn EJ, Eismon
FJ, et al, eds. The Cervical Spine. 2nd ed. Philadelphia, Pa: JB Lippincott
Co; 1989:11-32.
14. Bogduk N, Marsland A. The cervical zygapophysial joints as a source of
neck pain. Spine. Jun 1988;13(6):610-17.
15. A
 prill C, Dwyer A, Bogduk N. Cervical zygapophyseal joint pain patterns.
II: A clinical evaluation. Spine. Jun 1990;15(6):458-61.
16. Borenstein, Wiesel, Boden: Neck Pain, WB Saunders Co, Philadelphia,
1996, pp 179-183.
17. Crandall PH, Batzdorf U: Cervical spondylotic myelopathy. J Neurosurg
,1966; 25:57-59.
18. Patten J. Neurological differential diagnosis. 2d ed. New York: Springer,
1996
19. G
 ood DC, Couch JR, Wacaser L: Numb, clumsy hands and high cervical
spondylosis. Surg Neurol ,1984; 22:285-288.
20. O
 no K, Ebara S, uji T, et al: Myelopathy hand: new clinical signs of cervical
cord damage. J Bone Joint Surg, 1987; 69B:215-218.
21. Heller JG: The syndromes of degenerative cervical disease. Orthop Clin
North Am, 1992; 23:381-3.
22. P ikus HJ, Phillipis JM. Outcome of surgical decompression of the second
cervical root for cervicogenic headache. Neurosurgery 1996, 39:63-70.
23.  . (-).
, , 2006.
24. T ravell JG and Simons DG. Myofascial Pain and Dysfunction -The Trigger
Point Manual. Williams and Wilkins: Baltimore, 1983.
25. Wilson VJ. Physiological properties and central actions of neck muscle
spindles. In: ibid.
26. Bogduk N. Cervical causes of headache and dizziness. In: Grieve GP. Modern
Manual Therapy, Churchill-Livingstone: New York,1986.

6: 2W .
. . ) .
().
(), )
().

7: . .
) 1W .
3, 4, 5,
, ) 2W .

().

25

.


.

, 80%

10%
, ( ) .

, . (.
, ), , ,
1,2,3.

4. .
,
, 5. , ,
,

DNA ,
6 . , ,
777 . ,
shock 90kD
70kD

,
, 26

DNA
RNA. RNA ,
, .

. .
. ,
.
, I IV: , , .
, , , . ,
.
, ,
,
. , ,
7
. , ,
, 8. .
, . ,
, , . ( ) ,
.
, , , .
-


( 20% ), Cushing.
, , :
) , ( rebound)9
) 10,
,
.

,
, .
.
,
, , ,
.

D
D (
D, )
.
D , .
1,25 dihydroxyvitamin D3 , (VDR)11,12
, . ( ,
Langerhans, , , , , ).
D ,

. , , , , . , , , ,
13
.
, :
- 
- 
- 1
- 1 2
- 
-  14.
, , ,
.
.

D.

(3g/gr), , , ,
15
. ,
, 16.
210gr,
.

,
, 50g/gr.

.
,
.

. ,
. 100 gr
.
, .
(weekdays) (weekend)
, . /
52 ,
()
17
.

4 g/gr ,
18. ,
70gr.

,

0,05% 0,1%.
, . ,
tazarotenic acid , RAR,
19.
,
.
" ", 20% 20.
.
27


.
, , , ,
21 (30min 1h)
.
(UVB) 22.
X (FDA) , , 23.

, .

, 183824. . ,
pH
25.
, , ,
. ,
,
26. UVB .
30gr
6%. , 27.

. ,
. , .
.
, , 10%
28.

, ,
.
, . ,
Goeckerman (1925), UV
, ,
29.
DNA 30. -

28

. ' .

.

(1,8-dihydroxy-9- anthrone). 80 ,

. ,
31. 32.
,
33.
,
, . ,
, .
,
34.
.
,
10% 90% . , .
,
(short contact therapy)35.
1% 5 min,
, .

(, tacrolimus
pimecrolimus) , . tacrolimus pimecrolimus , ,
.

. , tacrolimus 0,1% 36 pimecrolimus
1% 37 ( ) ,
, 38.
.

. 1-3



.
,
3.

, 5 fluorouracil, zinc
pyrithione, spray , , .
-
. (.. )
,

.
, D

C FDA,
. , , ,
.23
, ,
.
, D, . , , ,
, .


, 39
.
,
D .

.
, .

1. Wan de Kerkhof PCM. The topical treatment of psoriasis. Clin Exper Dermatol 2005; 30:
205-208.
2. Wan de Kerkhof PCM, Barker J, Griffiths EMC et al. Psoriasis: consensus on topical therapies.
JEADV 2008; 22 (7): 859-870 .
3. Laws P, Young H Topical treatment of psoriasis. Expert Opin Pharmacotherap 2010; 11:
1999-2009.

30

4. Lebwohl M, and Suad A. Treatment of psoriasis. Part 1. Topical therapy and phototherapy.
J Am Acad Dermatol 2001; 45: 487-498.
5. Cornell RC. Clinical trials of topical corticosteroids in psoriasis: correlations with vasoconstrictor
assay. Int J Dermatol 1992; 31 (Suppl 1): 38-40.
6. Hughes J, Rustin M. Corticosteroids. Clin Dermatol 1997; 15:715-721
7. Menter Alan, Griffiths EMC. Current and future management of psoriasis. Lancet 2007;
370: 272-284.
8. Pardasani A.G, Feldman S.R, Clark A,R. Treatment of psoriasis: an algorithm-based approach
for primary care physicians. Am Fam Physician 2000; 61: 724-733.
9. Champion RH. Treatment of psoriasis. Br Med J 1966; 2: 993-995.
10. Du Vivier A, Stoughton RB. Tachyphylaxis to the action of topically applied corticosteroids.
Arch Dermatol 1975; 111: 581-583.
11. Peters BP, Weissman FC, Gill MA. Pathophysiology and treatment of psoriasis. Am J Health
Syst Pharm 2000; 57: 645-659.
12. Nagpal S, Lu J, Boehm MF. Vitamin D analogs: mechanism of action and therapeutic
applications. Curr Med Chem 2001; 8: 1661-1671.
13. Stewart DG, Lewis HM. Vitamin D analogues and psoriasis. J Clin Pharm Ther 1996;
21:143-148.
14. Jensen AM, Liado MB, Skov L, et al. Calcipotriol inhibits the proliferation of hyperproliferative
CD29 positive keratinocytes in psoriatic epidermis in the absence of an effect on the function
and number of antigen-presenting cells. Br J Dermatol 1998; 139: 984-991.
15. Langer A, Stapor W, Ambroziak M. Efficacy and tolerance of topical calcitriol 3 microgram/g
in psoriasis treatment: a review of our experience in Poland. Br J Dermatol 2001; 144
(Suppl.58): 11-16.
16. Ortonne JP, Humbert P, Nicolas JF, et al. Intra individual comparison of the cutaneous
safety and efficacy of calctriol 3g g-1 ointment and calcipotriol 50g g-1 ointment on
chronic plaque psoriasis localizes in facial, hairline, retroauricular or flexural areas. Br J
Dermatol 2003; 148: 326-333.
17. Kragballe K, Austad J, Barnes L, et al. A 52- week randomized safety study of a calcipotriol
/ betamethasone dipropionate two compound product (Dovobet / Daivobet / Taclonex)
in the treatment of psoriasis vulgaris. Br J Dermatol 2006; 154: 1155-1160.
18. Van de Kerkhof PC, Werfel T, Haustein UF et al. Tacalcitol ointment in the treatment of
psoriasis vulgaris: a multicentre, placebo-controlled, double-blind study on efficacy and
safety.Br J Dermatol 2002; 135: 758-765.
19. Chandraratna RAS. Tazarotene first of a new generation of receptor selective retinoids.
Br J Dermatol 1996; 135 (Suppl. 49): 18-25.
20. Gollnick HPM, Finzi AF, Marks R, et al. Optimising the use of tazarotene in clinical practice:
Consensus statement from the European Advisory Panel for Tazarotene (ZoracTM).
Dermatology 1999; 199: 40-46.
21. Veraldi. Short contact therapy with tazarotene in psoriasis vulgaris. Dermatology 2003;
26: 347-348.
22. Roeder A, Scaller M, Shafer-Korting M, Korting HC. Tazarotene: Therapeutic strategies in the
treatment of psoriasis, acne and photoaging. Skin Pharmacol Physiol 2004; 17:111-118.
23. L am J, Polifka EJ, Dohil AM. Safety of dermatologic drugs used in pregnant patients with
psoriasis and other inflammatory skin diseases. J Am Acad Dermatol 2008; 59: 295-315.
24. Weirich EG. Dermatopharmacology of salicylic acid. Dermatologica 1975; 15:114-116.
25. Davies M, Marks R. Studies on the effect of salicylic acid on normal skin. Br J Dermatol
1976: 95: 187-192.
26. Krochmal L, Wang JCT, Patel B, et al. Topical corticosteroid compounding: effects on
physiochemical stability and skin penetration rate. J Am Dermatol 1989; 979-984.
27. Lebwohl M. The role of salicylic acid in the treatment of psoriasis. Int J Dermatol 1999;
38: 16-24.
28. Hagemann I, Proksch E. Topical treatment by urea reduces epidermal hyperproliferation
and induces differentiation in psoriasis. Acta Derm Venereol 1996; 76: 353-356.
29. Thani GP, Sarkar R. Coal tar: past, present and future. Clin Exper Dermatol 2002; 27:
99-103.
30. Stoughton RB, DeQuoy P, Walter JF. Crude coal tar plus ultraviolet light suppresses DNA
synthesis in epidermis. Arch Dermatol 1978; 114: 43-45
31. Silverman A, Menter A, Hairston JL. Tars and anthralins. Dermatol Clin 1995; 13 (4):
817-833.
32. Pens D, Beyerle A, Rittner HL et al. Anti psoriatic drug anthralin activates JNK via lipid
peroxidation : mononuclear cells are more sensitive than keratinocytes. J Invest Dermatol
2000; 114: 688-692.
33. Fucks J, Nitschmann WN, Pacher L. The antipsoriatic compound anthralin influences
bioenergetic parameters and redox properties of energy transducing membranes. J Invest
Dermatol 1990; 94: 71-76.
34. Ramsay B, Lawrence CM, Bruce JM, Shuster S. The effects of triethanolamine application
on anthralin-induced inflammation and therapeutic effect in psoriasis. J Am Acad Dermatol
1990; 23: 73-76.
35. Schaefer H. Short-contact therapy. Arch Dermatol 1985; 121: 1505-1508.
36. Freeman AK, Linmowski GJ, Brady C et al. Tacrolimus ointment for the treatment of psoriasis
on the face and itertriginous areas. J Am Acad Dermatol 2003; 48: 564-568.
37. Gribetz C, Ling M, Lebwohl M et al. Pimecrolimus cream 1% in the Treatment of Intertriginous
Psoriasis: A Double- blind, Randomized Study. J Am Acad Dermatol 2004; 51: 731-738.
38. Nast A, Kopp I, Augustin M et al. German evidence-based guidelines for the treatment of
Psoriasis vulgaris (short version). Arch Dermatol Res 2007; 299: 111-138.
39. Norris AD. Mechanisms of action of topical therapies and the rationale for combination
therapy. J Am Acad Dermatol 2005; 53: S 17-25.

( ')
.
. /

. ,

, , .

,

. ,
.

Meckel.
,

.
, , .
4.
:

.
:




.

,

.
+/-

,

( 3):
,


.

1. ?
Iv.

99m
2. Tc

WilliamsSGJ. In Theraputic Gastrointestinal Endoscopy 2002 ()

4.

. , ,
, .

31

1:20.000

,

Laser
(,
, )
-


-


-

Laser
rgon plasma

3.

.

, ( ),
( ), ( )
( ).
H , , ,
.
4mm 1923G
,
.

1:20.000 ( )
, , 1-2ml , 10ml. ,
, ,
. , .
.
32

300IU 10 ml
, . 1ml 1:20.000.

. , ,

.
-
,
, . , .
(vasopressin)
0.2-0.4U/min ( 50%). , 70 %
. , ,
70%,
12%. ,
,
, .


rgon plasma
-.
,
, . H Argon plasma (PC) , .
rgon Plasma ,
. rgon Plasma,

Argon. () . , Argon
, ( 3). 5.

, , ( 70%) (
50%). , .

3. Argon .

,

.

, 1-2ml 1:20.000
.
Nd:YAG Laser .
.

 4
24
 10


72

.
5.

, 1-4% ,
( ) . ,
,
. , .


.





5-10min. 4.
.

, 1:20.000
.
( 250 ) , , ,
.

, 33

5.

6. .

.
2- 27%.

,


8. .
,

. ,
Argon plasma.

1. Berner JS, Mauer K, Lewis BS. Push and sonde enteroscopy for the diagnosis of obscure
gastrointestinal bleeding. Am J Gastroenterol 89: 2139-2142, 1994.
2. Binder HJ. Urgent endoscopy with endoscopic therapy for acute diverticular bleeding.
Gastroenterol 118: 978-980, 2000.
3. Chak A, Coopers GS, Canto MI, Pollack BJ, Sivak MV Jr. Enterscopy for the initial evaluation
of iron deficiency. Gastrointest Endosc 47: 144-144, 1998.
4. Chen PC, Wu CS, Liaw YF. Hemostatic effect of endoscopic local injection with hypertonic
saline-epinephrine solution and pure ethanol for digestive tract bleeding. Gastrointest
Endosc 32: 319-323, 1986.
5. Colacchio TA, Forde KA, Patsos TJ. Impact of modern diagnostic methods on the management
of active rectal bleeding. Ten year experience. Am J Surg 143: 607-610, 1982.
6. Cook DJ, Guyatt GH. Salena BJ, Laine LA. Endoscopic therapy for acute nonvariceal upper
gastrointestinal hemorrage; a meta-analysis. Gastroenterol 102:139-148, 1992.
7. Hammond KL, Beck DE, Hicks TC, et al.Implications of negative technetium 99m-labeled
red blood cell scintigraphy in patients presenting with lower gastrointestinal bleeding.
Am J Surg, 193:404-7; discussion 407-8, 2007.
8. Hotta T, Takifuji K, Tonoda S,Mishima H, Sasaki M, et al. Risk factors and management for
massive bleeding of an acute hemorrhagic rectal ulcer. Am. Surg. 75(1): 66-73 2009.
9. Iddan G, Meron G, Glukhovsky A, Swain P. Wireless capsule endoscopy. Nature 25:

34

7. .

405, 2000.
10. Kadakia SC, Angueira CE, Ward JA, Moore M. Gastrointestinal endoscopy in patiens
taking antiplatelel agents and anticoagulants: survey of ASGE members. Gastrointest
Endosc 44: 309-316, 1996.
11. Lewis BS. Small intestinal bleeding. Gastrointest Clin North Am 23: 67-91, 1994.
12. Lewis JD. Urgent endoscopy with endoscopic therapy for acute diverticular bleeding.
Comment. Gastroenterol 118: 979-980, 2000.
13. Longstreth GF. Epidemiology and outcome of patients hospitalized with acute lower
gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol 92: 419424, 1997.
14. Martin L, Trapero-Marugan M, Cantero Perona J, Moreno Otero R. Difficulties and
controversies in hospitalized patients with lower gastrointestinal bleeding. Rev Esp
Enferm Dig. 100(9): 560-4, 2008.
15. McKusick KA, Froelich J, Callahan RJ, Winzelberg GG, Strass HW. 99mTc red blood cells
for detection of gastrointestinal bleeding: experience with 80 patients. Am J Roentgenol
137: 1113-8, 1981.
16. Moncure AC, Tomkins RG, Athanasoulis CA, et al. Occult gastrointestinal bleeding: newer
techniques and diagnosis and therapy. Adv Surg 22: 141-177, 1989.
17. Sabharwal R, Vladica P, Chou R, et al.Helical CT in the diagnosis of acute lower
gastrointestinal haemorrhage.Eur J Radiol,58:273-9, 2006.
18. Saruta M, Papadakis KA. Capsule endoscopy in the evaluation and management of
inflammatory bowel disease: a future perspective. Expert Rev Mol Diagn. 9(1): 31-6,
2009.
19. Schock TR. Colonoscopic diagnosis and treatment of lower gastrointestinal bleeding.
Surg Cl North Am 69: 1309-1325, 1989.
20. Shapiro MJ. The role of the radiologist in the management of gastrointestinal bleeding.
Gastroenterol Clin North Am 23: 123-181, 1994.
21. Smith R, Copely DJ, Bolen FH. 99mTc RBC scintigraphy: correlation of gastrointestinal
bleeding rates with scintigraphic findings. Am J Roentgenol 148: 869-874, 1987.
22. Tulchinsky M. Lower gastrointestinal bleeding diagnosed dy reds blood cell scintigraphy
in a patient with a left ventricular assist device. Clin Nucl Med. 33(12): 856-8, 2008.
23. Vernava AM III, Moore BA, Longo WE, Jonhson FE. Lower gastrointestinal bleeding. Dis
Colon Rectum 40: 846-858, 1997.
24.Williams SGJ. Management of lower gastrointestinal bleeding. In: Theraputic Gastrointestinal
Endoscopy pp. 270, 2002.
25. Yang R, Laine L. Mucosal stripping: a complication of push enteroscopy. Gastroitest
Endosc 41: 156-158, 1995.
26. Zuckerman GR, Prakash C. Acute lower intestinal bleeding, 1: clinical presentation and
diagnosis. Gastrointest Endosc 48: 606-617, 1998.
27. Zuckerman GR, Prakash C. Acute lower intestinal bleeding, 2: etiology, therapy, and
outcomes. Gastrointest Endosc 49: 228-38, 1999.

. .
-,

, - , .
, , . , .
,
,
. ,
, . ,
.
,
.
, .

50%

35

. MD, PhD,

,

. , ,

()
,
(/ /).
, . , ,

. , : , ,
, , .

- ,
. , , ,
,
, .
, .., nm23 .
36

- ,
/ , . - - , ,
, ,
. . ,
,

,


,



(, ).

. .
-,

. ,
.
.
, .
.
, .
,
,
,
, .
.
, .

:
.

, -
.
.
1827
, ,
,
. , - ,
.
... 2006
. ,
, , ,
.

. ,
, . ,
. ,
, ,
, , . , , , , .
, , , , ;, !,
. , , , .
,

.

,
, , .
, , , , , ,
, , , , ,
, , . O ,
, , . .
, ,
;

37

 O
....
website: www.ellia.org
M 215, 115 25 l ./fax: 210 6753918, .: 6945 33334, 6944 54 2664
e-mail: info@ellia.org

O O
o

. o

..

Fax

e-mail

20 359/002002003471 .... Alpha Bank.

o o .

O/ .....

1. Avalsan 80 mg, Avalsan 160 mg 2. Avalsan 80 mg: 80 mg : 9,25mg, 1,08mg, 0,32mg (0,01mmol) Avalsan 160 mg:
160 mg : 18,50mg, 2,16mg, 0,63mg (0,03mmol) , . 6.1. 3. Avalsan 80 mg : , ,
, . Avalsan 160 mg : , , , . . 4. 4.1
(12 -10 ) (. 4.4 5.1)
() - (. 4.4 5.1). 4.2
Avalsan 80 mg . 2 4 . , ,
160 mg 320 mg. Avalsan . , , .
, 12 . 20mg , 40 mg, 80 mg 160 mg .
40 mg. 160 mg . , 80 mg 160 mg ,
. , . .. , , -,
. (. 4.4 5.1). . Avalsan 40 mg .
80 mg 160 mg . .
320 mg . . , , - (. 4.4. 5.1).
. Avalsan .
>10ml/ (. 4.4 5.2). , 80 mg. Avalsan (.
4.3, 4.4 5.2). Avalsan 18 . 4.3 . , .
(. 4.4 4.6). 4.4 , , ,
( ..) . . / - / -, ,
Avalsan, . , Avalsan.
Avalsan , , (BUN). , - , .
Avalsan . Avalsan, - .
, , (HOMC).
>10ml/. <10ml/ ,
( 4.2 5.2). , Avalsan (. 4.2 5.2). (AIIRA) .
AIIRA , . , AIIRA
, , , (. 4.3 4.6). ,
(. 4.2 5.1). , . .
(. 4.2). Avalsan ,
(. 4.2). , , - Avalsan (. 5.1).
. . (. 4.2). Avalsan
, (. 4.2).
- - (.. ), /
/ . , Avalsan .
. . . , Lapp (
) , . 23mg , . 4.5
. , . ,
. , , , , .
, . . (), COX-2, > 3g/, .
, . ,
. , . . , : , ,
, , , , , , . 4.6 , ,
. AIIRA, . AIIRA ,
. , AIIRA , , ,
. AIIRA ( , , ) (
(AIIRA)
, , ). 5.3 . AIIRA ,
(.
. AIIRA (. 4.3 4.4).
4.4). AIIRA
(.
, Avalsan , . 4.7
4.3 4.4).
. , . 4.8
, (), .
, . , .
, , : (>1/10), (>1/100 <1/10), (>1/1.000 <1/100), (>1/10.000 <1/1.000), (<1/10.000), . ,
. , .
(. 1) / .
. / : / (. 2)
4.9 Avalsan ,

, / . .

,

. . ,
, ,

. .



5. 5.1 : , ATC: C09CA03




, , (Ang II).



1 , . ,

2,

1. 1

( 20.000 ) 1 , 2.

,
,
, .

,

( ) .

,



. , ,



(p<0,05) , (2,6% 7,9% ).




, 19,5% , 19,0%

,

, 68,5% , (p<0,05).

, ,
,
Avalsan

4-6 . 24


,
. , 2 ,

,

4 . ,

. Avalsan (rebound hyperten

sion) . 2 ,
1

,
. MARVAL ( )

(UAE) (80-160 mg ) (5-10 mg ), 332

2 ( : 58 , 265 ) (: 58g/min; : 55,4g/min), ( <120

mol/l). 23 , UAE (p<0,001) 42% (-24,2 g/min; 95% :-40,4 -19,1) 3% (-1,7 g/min; 95% :-5,6 14,9)

. Avalsan Reduction of Proteinuria (DROP) UAE 391 ( =150/88 mmHg) 2,

,
(=102g/min; 20-700 g/min) ( =80 mol/l). 3 (160, 320 640 mg )


30 . UAE 2. 30 , UAE 36%

,
160 mg (95% :22 47%), 44% 320 mg (95% :31 54%). 160-320 mg UAE
2. VALsartan in Acute myocardial iNfarcTion (VALIANT) , , , - 14.703 ,
2
/ ( <40% <35%
). 12 10 , .
. . .
(19,9%), (19,5%), + (19,3%). .
, , , . , ,
, - ( ). .
, 4,2% , 4,8% + 3,4% .
1,1% , 1,3% , 0,8% .
. , - +, . ,
-, - . Val-HeFT , ,
5.010 , II (62%), III (36%) IV (2%) NYHA LVEF<40% (LVIDD) >2,9 cm/m2.
(93%), (86%), (67%) - (36%). . Avalsan Val-HeFT 254 mg. : ( )
( ) , ,
. (p=NS) (19,7%) (19,4%). 27,5% (95% ..:17 37%) (13,9% 18,5%).
( 21,9% 25,4% ) , , - .
(n=366), . 33% (95% ..:-6% 58%) (17,3% 27,1% )
44% (24,9% 42,5% ). -, (p=NS) (21,8%) (22,5%).
18,3% (95% ..:8% 28%) (31,0% 36,3%). Val-Heft,
NYHA , , , . , Minnesota Living with Heart Failure Quality of Life . LVIDD
. 5.2 : , 2-4 . Avalsan 23%. (
AUC) 40% (Cmax) 50%, 8 .
(AUC), , , . : 17 ,
. (94-97%), . : 20% .
( 10% (AUC) ). . : (t1/2<1 t1/2 9 ).
( 83% ) ( 13% ), . , 2 l/h
0,62 l/h ( 30% ). 6 . : -
. AUC Cmax (40 160 mg ). 1,7.
4,5 l/h. . , . ,
. , 30% , . , ,
( >10 ml/). < 10ml/ ,
( 4.2 4.4). . 70% , .
. (AUC) . , . Avalsan
(. 4.2, 4.3 4.4). 5.3 , ,
, . , (600 mg/kg/) , (
) (. 4.6). (600 mg/kg/) 18 mg/m2 ( 320 mg/ 60 ). ,
(200 600 mg/kg ) (, , )
( , ). (20 600 mg/kg/) 6 18 mg/
m2 ( 320 mg/ 60 ). , , ,
, . . ,
, . , . 6. 6.1
, , , , , , , , .
, , ( 171), Macrogol 4000 Avalsan 80 mg : , Avalsan 160 mg : /
(172) 6.2 6.3 2 6.4 30C. . 6.5
PVC/PE/PVDC () / 28 6.6 . 7. IASIS PHARMA 8.
Avalsan 80 mg: 55271/27-7-11, Avalsan 160 mg: 55272/27-7-11.

1. LODIPIN 2. & , : 5 mg amlodipine ( amlodipine besylate) , : 10 mg amlodipine ( amlodipine besylate) Amlodipine Besylate (BANM,
USAN) besilate (rINNM): C20H25ClN2O5.C6H6O3S=567,1 3-ethyl-5-methyl- 2- (2aminoethoxymethyl) - 4 - (2-chlorophenyl) - 1,4 - dihydro - 6 - methylpyridine - 3,5 - dicarboxylate benzenesulphonate 3. , 4. 4.1
. . 4.2 5 mg .
10 mg ( ) 6 , . .
(<18 ). , . , ( 5.2
). . . 4.4
. .
. ( 5.2 ). 4.3 , : ,
shock ( shock) ( ) ( Prinzmetal)
4.4 .
. (PRAISE2) ( V ) ,
, , (. 5.1 ).
( 28 ).
, . .
( 5.1 ). . .
. . 4.5
CYP3A4 : 22% 50% CYP3A4 , .
, CYP3A4. 50%, . , .
CYP3A4 (.. , , )
, .
MedDRA

CYP3A4. . CYP3A4 :
CYP3A4 . CYP3A4 {.. , St. John wort

,

( / )} .

:

CYP3A4. , , ,

/ () .
,

.

, , , (),
,

. . 4.6
(:
. ,
,
),

50 .

, ,

. .
(
.
)
. ,
, , ,


. 4.7
,
. , , ,
,

. 4.8 . placebo

, ,



MedDRA, : : >1/10, : >1/100 <1/10, :
(
>1/1.000 < 1/100, : >1/10.000 < 1/1.000, : < 1/10.000. (. ).
)
4.9 .

shock . ,

,
,

,
(
.
,
.

. .
2 10 mg .
)
, . 5.

ATC: C08CA01 5.1 (

.
,
,

.

: 1) H

,

(), .
, ,

. 2)

, .
(
Prinzmetal. ,
),
, , 24.
.
. ,
, ,

, ST 1 mm,
.



, ,

V , ,
*
. (PRAISE),

, ,
-V , , (),
,

,
. , (PRAISE -2)
Stevens-Johnson,
V , ,
Quincke,
, , .
, ,

, ,
,
(. 5.1
,
). , - -, ALLHAT (Antihypertensive and Lipid-Lowering Treatment to

Prevent Heart Attack Trial), : 2,5-10 mg/ ( )

10-40 mg/ ( )
12,5-25 mg/, . 33357 , 55 ,

, ,

4,9 ( ). , :
,
( 6 )

,

( 51,5 %), 2 (36,1 %), HDL-C < 35mg/dl (11,6 %),
,
(20,9 %), (21,9%). -

,

. : RR 0,98

95% CI [0,90-1,07] p=0,65. , ,

,

: RR 0,96 95% CI [0,89-1,02] p=0,20. 5.2.

,

, 6-12 .
,
,

64 80%. 21 /kg.

,

. in vitro 97,5%

. / 35-50
. 7-8 .
, 10%
60 % . .
(AUC) . AUC
. . .
10% . . .
( 5.2 ). 5.3
0.5, 1.25 2.5 mg/kg. ( , * 10 mg, mg/m)
, . .
, , , .
( 64 14 ) 10 mg/kg (8 *
10 mg, mg/m). * 50 kg. 6. 6.1 CELLULOSE MICROCRYSTALLINE, STARCH MAIZE, MAGNESIUM STEARATE : GELATINE,
TITANIUM DIOXIDE, SODIUM BETABISULFITE LODIPIN 5mg: QUINOLINE YELLOW, LODIPIN 10mg: IRON OXIDE (YELLOW), IRON OXIDE (BLACK) 6.2 . 6.3 36 250C 6.4
250C 6.5 Blisters VC/.: LODIPIN 5mg: BTx30 (BLIST3x10), LODIPIN
10mg: BTx30(BLIST3x10) 6.6 o . 7. - IASIS PHARMA 8. LODIPIN 5mg, LODIPIN 10mg: 18765/23-03-2010